226 Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells

Dupilumab, a therapeutic antibody blocking the eczematous type 2 immune response in atopic dermatitis (AD), has shown efficacy in many clinical trials and real-world observational studies. In addition to blepharitis and conjunctivitis, the de novo appearance of head/neck dermatitis is now recognized as a distinct side effect, occurring in up to 10% of patients at any time after dupilumab initiation. Histopathological features distinct from conventional AD suggest a drug effect, but the exact underlying mechanisms remain unknown.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Source Type: research